
Prof. MUDr. Petr Arenberger, DrSc, MBA, FCMA



<div class="skolitel">

</div>

Department of Dermatovenereology, Third Faculty of Medicine, Charles University and University Hospital of Kralovske Vinohrady

<https://www.lf3.cuni.cz/3LF-998.html>

Topic title

Epidemiology of mycosis fungoides patients

Description of scientific activity

Petr Arenberger is a Professor and Chairman at the Department of Dermatovenereology, Third Faculty of Medicine, Charles University, and University Hospital Kralovske Vinohrady, Prague.

He completed his medical degree at the Charles University, Prague, in 1984, and started his residency at the 1st Dept. of Dermatovenereology, Faculty Hospital, Prague 2. In 1987 he spent 1 year at the Dept. of Allergy, Faculty Hospital, Prague 10. Since 1988 he has been working at the Dept. of Dermatovenereology, Charles University, Third Faculty of Medicine, with 3 years at the Ludwig Maximilian University, Munich, Germany, and Stanford University, Palo Alto, California, USA.

Since 2001 he is a Chair at the Dept. of Dermatovenereology, Charles University, Third Medical Faculty, and University Hospital Kralovske Vinohrady, Prague, with broad interest in dermatology. According to Medline he authored and co-authored 146 publications in peer-reviewed journals, WOS is registering 4690 citations with the H-index of 23. His scientific interests include psoriasis, atopic eczema, melanoma and other epidermal and hematological malignant skin tumors, targeted therapy of skin cancer, pathophysiology of acne vulgaris, hidradenitis suppurativa, chronic wounds and bacterial and viral skin infections. At the same time he is involved in the dermatosurgery and and aesthetic dermatology.

Clinical trials – since 1995, more than 80 clinical trials as a Principle Investigator in psoriasis, atopic eczema, leg ulcers (chronic wounds), melanoma, basal cell carcinoma, Merkel cell carcinoma, squamous cell carcinoma, chronic urticaria, herpes zoster, herpes simplex etc.

Petr became a honorary member in 6 dermatological societies (German, Austrian, North American, Serbian, Hungarian and Czech). He is serving as president of the Czech Dermatovenereology Society and of the European Board of Dermatovenereology of the European Union of Medical Specialists, as a vice-president of the Czech Medical Association and as a board member of the Society for Corrective and Aesthetic Dermatology and of the Scientific Board of the Czech Medical Chamber. He became 2 awards - Silver Medal of the Czech Parliament – Senate for the life-long contribution to dermatovenereology 2017 and from the Patient Union - Best Physician of the year 2017.

Selected publications

Gollnick H.P.M., Arenberger P., Czarnecka-Operacz M.: Training requirements and recommendation for the specialty of dermatology and venereology European Standards of Postgraduate Medical Specialist Training. J Eur Acad Dermatol Venereol. 2019 Jul;33 Suppl 4(Suppl Suppl 4):3-25.

Arenberger P, Fialova A, Gkalpakiotis S, Pavlikova A, Puzanov I, Arenbergerova M. Melanoma antigens are biomarkers for ipilimumab response. J Eur Acad Dermatol Venereol. 2017 Feb;31(2):252-259.

Mandala M, Larkin J, Ascierto PA, Del Vecchio M, Gogas H, Cowey CL, Arance A, Dalle S, Schenker M, Grob JJ, Chiarion-Sileni V, Marquez-Rodas I, Butler MO, Di Giacomo AM, Lutzky J, De La Cruz-Merino L, Atkinson V, Arenberger P, Hill A, Fecher L, Millward M, Khushalani NI, de Pril V, Lobo M, Weber J. Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. J Immunother Cancer. 2021 Aug;9(8):e003188.

Selected or ongoing grants/clinical studies

Arenberger P., Pavelka K., Lukáš M.: Appropriate Immunization among Patients with Immune-Mediated Inflammatory Diseases (IMIDs) – quality improvement and data access project. Pfizer 2021 #69047423

A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy With Nivolumab Versus Placebo After Complete Resection of Stage IIB/C Melanoma

A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence

PhD Students

Number of PhD students currently studying: 4

Number of defended students with year of defence: 2 PhD. (2010 and 2020)